---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-261697"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:55:00.962936+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kalaris Therapeutics appoints Matthew Gall as CFO effective November 3, 2025

## Summary
- Matthew Gall appointed CFO and Treasurer effective Nov 3, 2025; succeeds Brett Hagan as principal financial officer.
- Annual base salary of $485,000; eligible for target bonus of up to 40% of base salary.
- Received incentive stock option for 235,000 shares vesting over 4 years at closing price on grant date.
- Severance: 9 months salary (12 months if within 12 months of change in control) plus COBRA and accelerated equity.
- Gall previously CFO of iTeos Therapeutics (June 2020 – Aug 2025).

## SEC filing metadata
- accession: 0001193125-25-261697
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525261697/0001193125-25-261697-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525261697/d14509d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-261697
- JSON: https://secwatch.observer/filing/0001193125-25-261697.json
- Plain text: https://secwatch.observer/filing/0001193125-25-261697.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.